Abstract Estrogen receptor-positive (ER+) breast cancer accounts for approximately 75% of
all breast cancers. Endocrine therapies, including selective ER modulators (SERMs) …

Nearly all fatalities arising from breast tumors are attributable to distant metastases. Breast
cancer liver metastasis (BCLM) is associated with poor prognoses, with the median survival …

Abstract The AURORA US Metastasis Project was established with the goal to identify
molecular features associated with metastasis. We assayed 55 females with metastatic …

Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-
positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, we …

PURPOSE CALGB 40601 assessed whether dual versus single human epidermal growth
factor receptor 2 (HER2)–targeting drugs added to neoadjuvant chemotherapy increased …

Breast cancer intrinsic subtypes (IS) are biologically distinct entities, characterized by
specific natural gene expression patterns 1, 2. The most widely accepted IS are the Luminal …

Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer.
However, different mechanisms play a role in treatment resistance. Here, we identified AXL …

Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with
oestrogen receptor positive (ER+) breast cancer (BC), but> 20% of patients will eventually …

The recognition of the immune system as a key component of the tumor microenvironment
(TME) led to promising therapeutics. Because such therapies benefit only subsets of …

Membrane proteins are a crucial class of therapeutic targets that remain challenging to
modulate using traditional occupancy-driven inhibition strategies or current proteolysis …